Avience Biomedicals IPO: Strong 62% GMP Signals Robust NSE SME Debut

Avience Biomedicals is poised for a highly anticipated stock market debut on the NSE SME platform this Thursday. With grey market indicators flashing bullish signals, investors are bracing for a significant premium at the time of listing.

Massive Subscription Numbers Drive Investor Frenzy

The ₹30.24 crore Initial Public Offering (IPO) has witnessed extraordinary demand, reflecting intense investor confidence in the company's business model. Comprising a fresh issue of 14.54 lakh shares, the IPO was subscribed a staggering 385.32 times during its three-day bidding window.

The demand was spearheaded by the Non-Institutional Investor (NII) segment, which saw a massive subscription of 597.23 times. Retail investors also showed immense appetite, oversubscribing their portion by 401.36 times. Meanwhile, Qualified Institutional Buyers (QIB) contributed to the momentum with a subscription rate of 196.77 times. This overwhelming participation suggests that both retail and institutional players see long-term value in the company's specialized niche.

Grey Market Premium Points to High Listing Gains

Current grey market activity suggests that Avience Biomedicals could deliver substantial immediate returns to its allottees. The shares are reportedly commanding a Grey Market Premium (GMP) of approximately 62% over the issue price of ₹208 per share.

If these market signals hold true, the estimated listing price could hover around ₹337. While GMP serves as an unofficial indicator of market sentiment and does not guarantee actual listing prices, the current spread indicates a very strong opening on the NSE SME platform.

Business Profile and Strategic Use of Funds

Incorporated in 2024, Avience Biomedicals has quickly established itself in the molecular diagnostic solutions sector. The company caters to the biotechnology, genomics, and in-vitro diagnostics (IVD) industries, offering a diverse portfolio that includes rapid test kits, biochemistry and hematology analysers, reagents, and various medical devices. Their client base spans pathology laboratories, hospitals, research centres, and government institutions both in India and internationally.

The company plans to utilize the capital raised from the IPO for strategic growth. A significant portion of the proceeds is earmarked for setting up a new manufacturing facility at the Medical Device Park under the Yamuna Expressway Industrial Development Authority in Uttar Pradesh. The remaining funds will be directed toward working capital requirements and general corporate purposes.

Robust Financial Performance

The company's financial trajectory appears positive as it scales its operations. For FY25, Avience Biomedicals reported a total income of ₹45.97 crore and a net profit of ₹7.23 crore. Looking at the recent performance for the nine months ended January 2026, the company posted revenue of ₹41.94 crore and a profit after tax (PAT) of ₹5.74 crore, demonstrating consistent revenue generation and profitability.

Key Takeaways

  • High Demand: The IPO was subscribed 385.32 times, with the NII segment leading the charge at 597.23 times.
  • Potential Listing Gains: A 62% grey market premium suggests an estimated listing price of approximately ₹337, up from the ₹208 issue price.
  • Expansion Plans: IPO proceeds will primarily fund a new manufacturing facility in Uttar Pradesh's Medical Device Park to bolster production capabilities.